Search research articles
Contact Us
Filters
Showing results (31-40 of 70) with videos related to
Page
of 7
Sort By:
Clinical Epigenetics
|
December 3, 2022
A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
Thatcher R Heumann, Marina Baretti, Elizabeth A Sugar, et al.
Cancer Chemotherapy and Pharmacology
|
June 16, 2018
Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors
Colin D Weekes, Lee S Rosen, Anna Capasso, et al.
Nature Medicine
|
August 12, 2025
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results
Zev A Wainberg, Colin D Weekes, Muhammad Furqan, et al.
Oncogene
|
October 31, 2012
The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment
L J Monteiro, P Khongkow, M Kongsema, et al.
Cancer Chemotherapy and Pharmacology
|
March 18, 2014
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors
Amita Patnaik, Patricia M LoRusso, Wells A Messersmith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 13, 2026
Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial
Hanny Al-Samkari, Joseph J Shatzel, Sandhya R Panch, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
March 31, 2020
Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas
Clifton Rodrigues, Thomas Hank, Motaz Qadan, et al.
Journal of the American College of Surgeons
|
February 2, 2023
Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis
Zhi Ven Fong, Fidel Lopez Verdugo, Carlos Fernandez-Del Castillo, et al.
JACC. Cardiooncology
|
April 5, 2021
The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil-Associated Coronary Vasospasm
Amna Zafar, Zsofia D Drobni, Ramya Mosarla, et al.
Annals of Surgery
|
October 21, 2020
Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma
Akhil Chawla, Motaz Qadan, Carlos Fernandez-Del Castillo, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 70) with videos related to
Sort By:
Page
of 7
Clinical Epigenetics
|
December 3, 2022
A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
Thatcher R Heumann, Marina Baretti, Elizabeth A Sugar, et al.
Cancer Chemotherapy and Pharmacology
|
June 16, 2018
Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors
Colin D Weekes, Lee S Rosen, Anna Capasso, et al.
Nature Medicine
|
August 12, 2025
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results
Zev A Wainberg, Colin D Weekes, Muhammad Furqan, et al.
Oncogene
|
October 31, 2012
The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment
L J Monteiro, P Khongkow, M Kongsema, et al.
Cancer Chemotherapy and Pharmacology
|
March 18, 2014
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors
Amita Patnaik, Patricia M LoRusso, Wells A Messersmith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 13, 2026
Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial
Hanny Al-Samkari, Joseph J Shatzel, Sandhya R Panch, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
March 31, 2020
Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas
Clifton Rodrigues, Thomas Hank, Motaz Qadan, et al.
Journal of the American College of Surgeons
|
February 2, 2023
Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis
Zhi Ven Fong, Fidel Lopez Verdugo, Carlos Fernandez-Del Castillo, et al.
JACC. Cardiooncology
|
April 5, 2021
The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil-Associated Coronary Vasospasm
Amna Zafar, Zsofia D Drobni, Ramya Mosarla, et al.
Annals of Surgery
|
October 21, 2020
Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma
Akhil Chawla, Motaz Qadan, Carlos Fernandez-Del Castillo, et al.
Page
of 7